Smoking Prevalence, Mortality Ranges Widely From State to State

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 4
Volume 10
Issue 4

WASHINGTON-Smoking prevalence varies considerably from state to state among both adults and students, according to new data from the Centers for Disease Control and Prevention (CDC). In 1999, adult prevalence ranged from 13.9% in

WASHINGTON—Smoking prevalence varies considerably from state to state among both adults and students, according to new data from the Centers for Disease Control and Prevention (CDC). In 1999, adult prevalence ranged from 13.9% in Utah to 31.5% in Nevada. For students (grades 9-12), the rate varied between a low of 11.9% in Utah to a high of 43.6% in South Dakota. Smoking-related deaths ranged from 188 per 100,000 population in Utah to 469 per 100,000 in Nevada. Kentucky had the highest lung cancer mortality rate in 1997, 53.2 per 100,000, and Utah had the lowest, 14.2 per 100,000.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content